Digestion of Flexible Linkers
CD BioGlyco has a professional Glycoengineering Platform with multiple world-leading technologies to help customers comprehensively promote the digestion of flexible linkers.
Overview of Flexible Linkers
Designing fusion proteins composed of multiple protein domains is a very popular way of designing new protein functions. The linker not only separates the two protein domains, but its properties directly affect the functional properties of the fusion protein. The most commonly used linkers for linking protein or peptide domains are flexible linkers.
The most commonly used flexible linkers have sequences consisting primarily of stretches of glycine (Gly) and serine (Ser) residues ("GS" linker). Currently, the most widely used flexible linkers have the sequence (Gly-Gly-Gly-Gly-Ser)n. In addition to GS linkers, many other flexible linkers have emerged for recombinant fusion proteins. These flexible linkers, including KESGSVSSEQLAQFRSLD and EGKSSGSGSESKST, have been used to construct biologically active single-chain variable fragments (scFvs). The Gly and Ser residues in the linker were designed to provide flexibility, whereas glutamic acid (Glu) and lysine (Lys) were added to improve the solubility.
Flexible linkers with good flexibility and solubility are often rich in small or polar amino acids, such as Gly and Ser. Flexible linkers with this property are very useful when the fusion protein domains require certain movements or interactions (e.g. scFv).
Key Technologies
We utilize a selection of highly specific proteases and engineered enzymes developed in-house to selectively cleave flexible linker regions. These enzymes are optimized for diverse linker sequences, ensuring precise digestion without compromising the structural integrity of the antibody's functional domains.
Digestion of Flexible Linkers at CD BioGlyco
Intermediate analytical strategies provide a means to rapidly improve mass spectrometry quality. However, the new model brings new analytical challenges.
CD BioGlyco provides specific enzymes to digest flexible glycine-rich fusion protein linkers including GS and polyglycine (G) linkers. This enzyme enables the isolation of different domains of multifunctional fusion proteins to facilitate characterization and increase protein understanding. This facilitates intermediate-level analysis of fusion proteins that can both reduce overall sample complexity and enable domain-specific recognition and monitoring of post-translational modifications. Fusion proteins and various monoclonal antibody fragments containing glycine-rich linkers can be characterized in detail by intermediate methods.
- Project Consulting and Project Design
Our expert team will work closely with you to understand your project goals and the unique characteristics of your antibody. We will analyze your specific antibody structure and linker sequence and customize digestion and glycosylation strategies to perfectly meet your specific needs.
- Targeted Enzymatic Digestion of Flexible Linkers
This is the core of our professional services. We use specific enzymes to selectively and efficiently digest glycine-rich flexible fusion protein linkers, including GS and polyglycine (G) linkers. This targeted enzymatic digestion technology precisely separates distinct functional domains in multifunctional fusion proteins and monoclonal antibody fragments, providing in-depth insights into antibody structure and function.
- Stringent Purification and Quality Control
Following enzymatic digestion, advanced chromatography techniques are used to remove all impurities, including residual enzyme and linker peptides. Multi-point quality control using advanced mass spectrometry (MS) ensures complete removal of the linker peptide, ensuring product purity and integrity.
- Advanced Glycoengineering and Modification
The purified fragments are free of steric hindrance, providing an ideal foundation for subsequent glycoengineering. We collaborate with you to perform a variety of customized glycan modifications using enzymatic and chemoenzymatic methods to achieve the desired homogeneous glycoforms.
- Final Report and Product Delivery
Upon project completion, we provide a comprehensive report containing a complete breakdown of the experimental steps, quality control data, and analytical results. The final, high-quality glycoengineered product will be delivered to you along with all supporting documentation and a clear follow-up process.
Workflow
Publication Data
Journal: Scientific Reports
IF: 3.8
Published: 2022
Results: This study investigates the impact of linker sequences on the in vitro and in vivo properties of an anti-vascular endothelial growth factor (VEGF) scFv derived from Bevacizumab. Two linkers were compared: a repetitive GS linker (L2) and a non-repetitive linker (L1) with similar flexibility but lower predicted immunogenicity. In vitro analyses revealed that L1 exhibited superior properties, including a higher monomer ratio, greater thermal stability, and lower immunogenicity scores, though L2 showed approximately threefold higher binding affinity to VEGF. In vivo, both scFvs inhibited angiogenesis more effectively than bevacizumab, while no significant difference in in vivo efficacy was observed between the two linkers. This is the first study to compare scFv linker effects in a zebrafish model, highlighting that non-repetitive linkers offer advantages in developability (stability, monomericity, immunogenicity) without compromising in vivo anti-angiogenic activity.
Fig.1 Binding kinetics of Bevacizumab, L1, and L2 fragments to their antigen, VEGF. (Arslan, et al., 2022)
Applications
- Through precise glycoengineering, we help clients develop new therapeutics with enhanced properties. This includes optimizing antibody-dependent cellular cytotoxicity (ADCC), improving complement-dependent cytotoxicity (CDC), and designing antibodies with greater stability and longer half-lives.
- By targeting and modifying glycan sites, we help clients develop antibodies for immunoassays and biosensors with enhanced binding affinity and reduced background noise.
- By isolating specific functional domains, we enable detailed investigation of antibody structure and function, as well as the complex role of glycans in protein-protein interactions.
Advantages of Us
- One-stop service for the digestion of flexible linkers
- The enzymatic digestion requires no reducing agents or cofactors
- Customize the experimental program as needed
- Cutting-edge technology and professional research team
Frequently Asked Questions
CD BioGlyco provides one-stop Antibody Digestion Services and ensures the continuity and transparency of the experimental process. We will continue to improve our standards to meet customers' glycobiology research needs with high quality. If you are interested in our services, please contact us for more details without any hesitation.
Associated Services
Reference
- Arslan, M.; et al. Effect of non-repetitive linker on in vitro and in vivo properties of an anti-VEGF scFv. Scientific Reports. 2022, 12(1): 5449. (Open Access)
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform




